Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2010
08/24/2010CA2213560C Pharmaceutical compositions for controlled release of soluble receptors
08/24/2010CA2204512C Lgmd gene coding for a calcium dependent protease
08/24/2010CA2181924C Diagnosis and treatment of infections due to streptococci and enterococci
08/19/2010WO2010094031A1 Recombinant human follicle stimulating hormone antagonists and methods of use thereof
08/19/2010WO2010093941A2 COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS
08/19/2010WO2010093925A2 PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE
08/19/2010WO2010093918A1 Apolipoprotein a-i mimics
08/19/2010WO2010093904A2 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
08/19/2010WO2010093843A2 Hcv combination therapies
08/19/2010WO2010093814A1 Methods of treating dementia using a gm-csf antagonist
08/19/2010WO2010093802A2 Therapeutic method for increasing pancreatic beta cell mass
08/19/2010WO2010093771A1 Combination vegfr2 therapy with temozolomide
08/19/2010WO2010093738A1 Preparation of annexin derivatives
08/19/2010WO2010093627A2 Fibronectin type iii domain based scaffold compositions, methods and uses
08/19/2010WO2010093324A1 Use of antisecretory factors (af) for optimizing cellular uptake
08/19/2010WO2010093322A1 Methods for identifying therapeutic agents modulating activity of the igf2 repressor zbed6
08/19/2010WO2010093284A1 Dipeptide mimetics of ngf and bdnf neurotrophins
08/19/2010WO2010093245A1 Antimicrobial peptides based on cmap27
08/19/2010WO2010092577A2 COMPLEMENT C3a DERIVED DIMERIC PEPTIDES AND USES THEREOF
08/19/2010WO2010092571A2 Short beta-defensin-derived peptides
08/19/2010WO2010092485A2 Combined treatment of multiple sclerosis
08/19/2010WO2010092419A1 Combined treatment of multiple sclerosis
08/19/2010WO2010092224A1 Biopolymer, implant comprising it and uses thereof
08/19/2010WO2010092218A2 Use of cardiotrophin- 1 for the treatment of metabolic diseases
08/19/2010WO2010092112A1 Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
08/19/2010WO2010091542A1 Anti-tumor, anti-bacterial and/or anti-viral applications of ctla4ig and derivatives thereof.
08/19/2010WO2010074794A3 Membrane transduction peptides, polynucleotides, and methods
08/19/2010WO2010068917A3 Compositions and methods for promoting vascular barrier function and treating pulmonary fibrosis
08/19/2010WO2010068414A9 Methods for treating obesity related disease
08/19/2010WO2010065116A9 The use of il-27-p28 to antagonize il-6 mediated signaling
08/19/2010WO2010062587A4 Nucleic acids encoding peptides for treating wounds, anti-angiogenic compounds, and uses thereof
08/19/2010WO2010062057A3 Composition for promoting implantation of embryo or pregnancy
08/19/2010WO2010056472A3 Compositions and methods of use for soluble thrombomodulin variants
08/19/2010WO2010054381A3 Method of treating cancer with a combination of a proteasome inhibitor and salubrinal
08/19/2010WO2010051533A3 Compositions of engineered human arginases and methods for treating cancer
08/19/2010WO2010048308A3 Natriuretic polypeptides
08/19/2010WO2010047493A3 Composition for the treatment of cancer, containing a kir 2.2 inhibitor
08/19/2010WO2010042691A8 Compositions and methods for detection of antibodies specific for anaplasma phagocytophilum (aph) and anaplasma platys (apl)
08/19/2010WO2010041889A3 Pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease
08/19/2010WO2010033862A3 Methods for treating cancer using npar agonists
08/19/2010WO2010033249A3 Compositions of and methods of using ligand dimers
08/19/2010WO2010025421A3 Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
08/19/2010US20100212037 Mia-2 protein
08/19/2010US20100212036 Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy
08/19/2010US20100212033 Novel ubiquitin lifases as therapeutic tragets
08/19/2010US20100211015 Composition comprising hyaluronidase glycoprotein that is active at neutral pH and contains at least one sugar moiety that is covalently attached to an asparagine for use in treatment of diabetic disorders
08/19/2010US20100210818 Nucleic acids encoding the human alex1 protein
08/19/2010US20100210817 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
08/19/2010US20100210729 Methods of inducing terminal differentiation
08/19/2010US20100210714 Her-2/neu DNA Vaccine Having Anti-Cancer Activity
08/19/2010US20100210603 Novel sulfonamide inhibitors of aspartyl protease
08/19/2010US20100210568 Thyrotropin releasing hormone for therapeutic applications
08/19/2010US20100210567 Use of a tuftsin as a therapeutic agent
08/19/2010US20100210566 Azapeptides as cd36 binding compounds
08/19/2010US20100210565 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
08/19/2010US20100210564 Drug or food containing a peptide
08/19/2010US20100210563 Metastasis-specific peptides and their diagnostic and therapeutic applications
08/19/2010US20100210562 Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent
08/19/2010US20100210561 Use of peptide as a therapeutic agent
08/19/2010US20100210560 Neurotensin receptor agonists and opioid receptor agonists
08/19/2010US20100210559 Trap-14 as a therapeutic agent
08/19/2010US20100210558 Minigastrin as a therapeutic agent
08/19/2010US20100210557 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent
08/19/2010US20100210556 Use of a peptide as a therapeutic agent
08/19/2010US20100210555 Use of a laminin peptide as a therapeutic agent
08/19/2010US20100210554 Therapeutic uses of gastrin- 1 and g- pen-grgdspca
08/19/2010US20100210553 Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-arg as a therapeutic agent
08/19/2010US20100210552 Human glucagon-like peptide-1 mimics and their use in the treatment of diabetes and related conditions
08/19/2010US20100210547 Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol)
08/19/2010US20100210546 Combination chemotherapy with chlorotoxin
08/19/2010US20100210545 Preventive/remedy for cancer
08/19/2010US20100210544 Peptides and pharmaceucal compositions for treating connective tissue
08/19/2010US20100210543 Aldehyde-Tagged Protein-Based Drug Carriers and Methods of Use
08/19/2010US20100210542 Methods of Treating Disorders with Group I mGluR Antagonists
08/19/2010US20100210541 Biomarkers for Appetite Regulation
08/19/2010US20100210540 Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
08/19/2010US20100210539 Use of peptide ll-37 as a therapeutic agent
08/19/2010US20100210538 Therapeutic uses of intermedin 47 and 53 peptides
08/19/2010US20100210537 Use of a defensin peptide as a therapeutic agent
08/19/2010US20100210536 Use of leptin (22-56 ) as a therapeutic agent
08/19/2010US20100210535 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof
08/19/2010US20100210534 Use of a peptide as a therapeutic agent
08/19/2010US20100210533 Use of urocortin and corticotropin-releasing factor as therapeutic agents
08/19/2010US20100210532 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent
08/19/2010US20100210531 Agents with angiogenic and wound healing activity
08/19/2010US20100210530 Extracellular matrix compositions
08/19/2010US20100210529 P53 peptide vaccine
08/19/2010US20100210528 Compositions, methods and uses for inhibition and/or treatment of influenza infection
08/19/2010US20100210527 Pro- and anti-angiogenic treatments
08/19/2010US20100210526 Oral administration of a calcitonin
08/19/2010US20100210525 Combined preparation of a thiazide diuretic and a loop diuretic
08/19/2010US20100210524 Novel estrogen receptor ligands
08/19/2010US20100210523 Modulation of activity of proneurotrophins
08/19/2010US20100210522 Method for determining presence of cancer in a sample by assaying for expression of dppa-2 nucleotide sequences
08/19/2010US20100210521 Compositions and methods for modulating ampa receptor-mediated excitotoxicity
08/19/2010US20100210520 Regulation of function of angiopoietin
08/19/2010US20100210519 Peptide slow-release formulations
08/19/2010US20100210518 Peg-lipid conjugates for increasing the solubility of drug compounds
08/19/2010US20100210517 Cyclic receptor-associated protein (rap) peptides
08/19/2010US20100210516 Growth Factor Binding Molecules
1 ... 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 ... 3163